{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:33:03Z","timestamp":1778725983132,"version":"3.51.4"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s40266-015-0282-9","type":"journal-article","created":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T06:05:45Z","timestamp":1435730745000},"page":"569-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma"],"prefix":"10.1007","volume":"32","author":[{"given":"David C.","family":"Broadway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Cate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,2]]},"reference":[{"key":"282_CR1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137.","journal-title":"Br J Ophthalmol."},{"key":"282_CR2","first-page":"190","volume":"17","author":"JC Tsai","year":"2006","unstructured":"Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006;17:190\u20135.","journal-title":"Curr Opin Ophthalmol."},{"key":"282_CR3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0161-6420(98)94031-3","volume":"105","author":"MD Wensor","year":"1998","unstructured":"Wensor MD, McCarty CA, Stanislavsky YL, et al. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology. 1998;105:733\u20139.","journal-title":"Ophthalmology."},{"key":"282_CR4","doi-asserted-by":"crossref","unstructured":"Mitchell P, Smith W, Attebo K. et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103:1661\u20131669.","DOI":"10.1016\/S0161-6420(96)30449-1"},{"key":"282_CR5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0161-6420(94)31090-6","volume":"101","author":"I Dielemans","year":"1994","unstructured":"Dielemans I, Vingerling JR, Wolfs RC, et al. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology. 1994;101:1851\u20135.","journal-title":"Ophthalmology."},{"key":"282_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0002-9394(82)90073-3","volume":"94","author":"GS Martinez","year":"1982","unstructured":"Martinez GS, Campbell AJ, Reinken J, et al. Prevalence of ocular disease in a population study of subjects 65 years old and older. Am J Ophthalmol. 1982;94:181\u20139.","journal-title":"Am J Ophthalmol."},{"key":"282_CR7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.1991.03470030069026","volume":"266","author":"JM Tielsch","year":"1991","unstructured":"Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266:369\u201374.","journal-title":"JAMA."},{"key":"282_CR8","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0161-6420(92)31774-9","volume":"99","author":"BE Klein","year":"1992","unstructured":"Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992;99:1499\u2013504.","journal-title":"Ophthalmology."},{"key":"282_CR9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/archopht.1994.01090170088028","volume":"112","author":"HA Quigley","year":"1994","unstructured":"Quigley HA, Enger C, Katz J, et al. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol. 1994;112:644\u20139.","journal-title":"Arch Ophthalmol."},{"key":"282_CR10","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archopht.1995.01100070092031","volume":"113","author":"MC Leske","year":"1995","unstructured":"Leske MC, Connell AM, Wu SY, et al. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113:918\u201324.","journal-title":"Arch Ophthalmol."},{"key":"282_CR11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0161-6420(02)01040-0","volume":"109","author":"BN Mukesh","year":"2002","unstructured":"Mukesh BN, McCarty CA, Rait JL, et al. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology. 2002;109:1047\u201351.","journal-title":"Ophthalmology."},{"key":"282_CR12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/archopht.124.11.1625","volume":"124","author":"DS Friedman","year":"2006","unstructured":"Friedman DS, Jampel HD, Munoz B, et al. The prevalence of open-angle glaucoma among Blacks and Whites 73 years and older: The Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol. 2006;124:1625\u201330.","journal-title":"Arch Ophthalmol."},{"key":"282_CR13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ophtha.2007.03.017","volume":"115","author":"MC Leske","year":"2008","unstructured":"Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008;115:85\u201393.","journal-title":"Ophthalmology."},{"key":"282_CR14","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.ophtha.2011.02.014","volume":"118","author":"Y Zheng","year":"2011","unstructured":"Zheng Y, Lavanya R, Wu R, et al. Prevalence and causes of visual impairment and blindness in an urban Indian population: the Singapore Indian Eye Study. Ophthalmology. 2011;118:1798\u2013804.","journal-title":"Ophthalmology."},{"key":"282_CR15","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ophtha.2012.05.030","volume":"119","author":"X Jiang","year":"2012","unstructured":"Jiang X, Varma R, Wu S, et al. Baseline risk factors that predict the development of open-angle glaucoma in a population: The Los Angeles Latino Eye Study. Ophthalmology. 2012;119:2245\u201353.","journal-title":"Ophthalmology."},{"key":"282_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000309530","volume":"191","author":"R David","year":"1985","unstructured":"David R, Tessler Z, Yassur Y. Epidemiology of acute angle-closure glaucoma: incidence and seasonal variations. Ophthalmologica. 1985;191:4\u20137.","journal-title":"Ophthalmologica."},{"key":"282_CR17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF02153405","volume":"225","author":"J Teikari","year":"1987","unstructured":"Teikari J, Raivio I, Nurminen M. Incidence of acute glaucoma in Finland from 1973 to 1982. Graefes Arch Clin Exp Ophthalmol. 1987;225:357\u201360.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"282_CR18","first-page":"625","volume":"37","author":"K Fujita","year":"1996","unstructured":"Fujita K, Negishi K, Fujiki K, et al. Epidemiology of acute angle-closure glaucoma. Jpn J Clin Ophthalmol. 1996;37:625\u20139.","journal-title":"Jpn J Clin Ophthalmol."},{"key":"282_CR19","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1001\/archopht.1997.01100160606014","volume":"115","author":"SK Seah","year":"1997","unstructured":"Seah SK, Foster PJ, Chew PT, et al. Incidence of acute primary angle-closure glaucoma in Singapore. An island-wide survey. Arch Ophthalmol. 1997;115:1436\u201340.","journal-title":"Arch Ophthalmol."},{"key":"282_CR20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/bjo.84.9.990","volume":"84","author":"TY Wong","year":"2000","unstructured":"Wong TY, Foster PJ, Seah SK, et al. Rates of hospital admissions for primary angle closure glaucoma among Chinese, Malays, and Indians in Singapore. Br J Ophthalmol. 2000;84:990\u20132.","journal-title":"Br J Ophthalmol."},{"key":"282_CR21","first-page":"118","volume":"7","author":"JS Lai","year":"2001","unstructured":"Lai JS, Liu DT, Tham CC, et al. Epidemiology of acute primary angle-closure glaucoma in the Hong Kong Chinese population: prospective study. Hong Kong Med J. 2001;7:118\u201323.","journal-title":"Hong Kong Med J."},{"key":"282_CR22","first-page":"41","volume":"26","author":"M Ivanisevi\u0107","year":"2002","unstructured":"Ivanisevi\u0107 M, Erceg M, Smoljanovi\u0107 A, et al. The incidence and seasonal variations of acute primary angle-closure glaucoma. Coll Antropol. 2002;26:41\u20135.","journal-title":"Coll Antropol."},{"key":"282_CR23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313.","journal-title":"Arch Ophthalmol."},{"key":"282_CR24","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol."},{"key":"282_CR25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48\u201356.","journal-title":"Arch Ophthalmol"},{"key":"282_CR26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","volume":"126","author":"The Collaborative Normal Tension Glaucoma Study Group","year":"1998","unstructured":"The Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498\u2013505.","journal-title":"Am J Ophthalmol"},{"key":"282_CR27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0161-6420(00)00518-2","volume":"108","author":"DR Anderson","year":"2001","unstructured":"Anderson DR, Drance SM, Schulzer M. Natural history of normal-tension glaucoma. Ophthalmology. 2001;108:247\u201353.","journal-title":"Ophthalmology."},{"key":"282_CR28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0002-9394(01)00964-3","volume":"131","author":"S Drance","year":"2001","unstructured":"Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001;131:699\u2013708.","journal-title":"Am J Ophthalmol."},{"key":"282_CR29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/B978-0-7020-5193-7.00009-1","volume-title":"Glaucoma: medical diagnosis and therapy","author":"AS Hafez","year":"2015","unstructured":"Hafez AS, Lesk MR. Role of ocular blood flow in the pathogenesis of glaucoma. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma: medical diagnosis and therapy. London: Elsevier Saunders; 2015. p. 88\u201397."},{"key":"282_CR30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/B978-0-7020-5193-7.00033-9","volume-title":"Glaucoma: medical diagnosis and therapy","author":"AP Tanna","year":"2015","unstructured":"Tanna AP. Normal-tension glaucoma. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma: medical diagnosis and therapy. London: Elsevier Saunders; 2015. p. 378\u201386."},{"key":"282_CR31","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","volume":"108","author":"PR Lichter","year":"2001","unstructured":"Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943\u201353.","journal-title":"Ophthalmology."},{"key":"282_CR32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The Advanced Glaucoma Intervention Study","year":"2000","unstructured":"The Advanced Glaucoma Intervention Study. (AGIS) Investigators. The Advanced Glaucoma Intervention Study (AGIS 7): the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u201340.","journal-title":"Am J Ophthalmol."},{"key":"282_CR33","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2004.02.017","volume":"111","author":"K Nouri-Mahdavi","year":"2004","unstructured":"Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study (AGIS). Ophthalmology. 2004;111:1627\u201335.","journal-title":"Ophthalmology."},{"key":"282_CR34","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archopht.126.8.1030","volume":"126","author":"BC Chauhan","year":"2008","unstructured":"Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126:1030\u20136.","journal-title":"Arch Ophthalmol."},{"key":"282_CR35","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archophthalmol.2010.196","volume":"128","author":"BC Chauhan","year":"2010","unstructured":"Chauhan BC, Mikelberg FS, Artes PH, et al. Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol. 2010;128:1249\u201355.","journal-title":"Arch Ophthalmol."},{"key":"282_CR36","author":"DF Garway-Heath","year":"2014","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost treatment for open angle glaucoma. The United Kingdom Glaucoma Treatment Study: a multicentre, randomised, placebo-controlled clinical trial. Lancet. 2014. doi: 10.1016\/S0140-6736(14)62111-5 .","journal-title":"Lancet."},{"key":"282_CR37","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.ophtha.2007.02.001","volume":"114","author":"DS Friedman","year":"2007","unstructured":"Friedman DS, Freeman E, Munoz B, et al. Glaucoma and mobility performance: the Salisbury Eye Evaluation Project. Ophthalmology. 2007;114:2232\u20137.","journal-title":"Ophthalmology."},{"key":"282_CR38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1167\/iovs.06-0886","volume":"48","author":"SA Haymes","year":"2007","unstructured":"Haymes SA, LeBlanc RP, Nicholela MT, et al. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007;48:1149\u201355.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"282_CR39","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ophtha.2006.02.062","volume":"113","author":"AJ Lee","year":"2006","unstructured":"Lee AJ, Wang JJ, Kifley A, et al. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006;113:1069\u201376.","journal-title":"Ophthalmology."},{"key":"282_CR40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00417-004-0858-2","volume":"242","author":"K Grodum","year":"2004","unstructured":"Grodum K, Heijl A, Bengtsson B. Glaucoma and mortality. Graefes Arch Clin Exp Ophthalmol. 2004;242:397\u2013401.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"282_CR41","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archopht.123.6.807","volume":"123","author":"MD Knudtson","year":"2005","unstructured":"Knudtson MD, Klein BE, Klein R, et al. Age-related eye disease, quality of life, and functional activity. Arch Ophthalmol. 2005;123:807\u201314.","journal-title":"Arch Ophthalmol."},{"key":"282_CR42","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0161-6420(03)00450-0","volume":"110","author":"PH Borger","year":"2003","unstructured":"Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. Ophthalmology. 2003;110:1292\u20136.","journal-title":"Ophthalmology."},{"key":"282_CR43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.1977.04450040067008","volume":"95","author":"TJ Zimmerman","year":"1977","unstructured":"Zimmerman TJ, Kaufman HE, Timolo S. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601\u20134.","journal-title":"Arch Ophthalmol."},{"key":"282_CR44","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1001\/archopht.1978.03910060433007","volume":"96","author":"RL Coakes","year":"1978","unstructured":"Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol. 1978;96:2045\u20138.","journal-title":"Arch Ophthalmol."},{"key":"282_CR45","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1018938310628","volume":"11","author":"A Urtti","year":"1994","unstructured":"Urtti A, Rouhiainen H, Kaila T, Saana V. Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. Pharm Res. 1994;11:1278\u201382.","journal-title":"Pharm Res."},{"key":"282_CR46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0002-9394(86)90532-5","volume":"102","author":"WL Nelson","year":"1986","unstructured":"Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978\u20131985. Am J Ophthalmol. 1986;102:606\u201311.","journal-title":"Am J Ophthalmol."},{"key":"282_CR47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/jama.1986.03370030077031","volume":"255","author":"J Avorn","year":"1986","unstructured":"Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed \u00df-blockers. JAMA. 1986;255:357\u201360.","journal-title":"JAMA."},{"key":"282_CR48","first-page":"39","volume":"100","author":"HE Kaeser","year":"1984","unstructured":"Kaeser HE. Drug-induced myasthenic syndromes. Acta Neurologica Scandinavica. 1984;100:39\u201347.","journal-title":"Acta Neurologica Scandinavica."},{"key":"282_CR49","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1345\/aph.1A178","volume":"36","author":"CL Alexander","year":"2002","unstructured":"Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36:504\u201311.","journal-title":"Ann Pharmacother."},{"key":"282_CR50","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","volume":"53","author":"CB Toris","year":"2008","unstructured":"Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53:S107\u201320.","journal-title":"Surv Ophthalmol."},{"key":"282_CR51","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S0039-6257(97)80016-1","volume":"41","author":"A Alm","year":"1997","unstructured":"Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41:S105\u201310.","journal-title":"Surv Ophthalmol."},{"key":"282_CR52","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/archopht.117.10.1305","volume":"117","author":"J Hedner","year":"1999","unstructured":"Hedner J, Everts B, M\u00f6ller CS. Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. Arch Ophthalmol. 1999;117:1305\u20139.","journal-title":"Arch Ophthalmol."},{"key":"282_CR53","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0039-6257(02)00302-8","volume":"47","author":"B Sj\u00f6quist","year":"2002","unstructured":"Sj\u00f6quist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47:S6\u201312.","journal-title":"Surv Ophthalmol."},{"key":"282_CR54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00055735-200004000-00005","volume":"11","author":"RA Schumer","year":"2000","unstructured":"Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000;11:94\u2013100.","journal-title":"Curr Opin Ophthalmol."},{"key":"282_CR55","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.survophthal.2003.12.014","volume":"49","author":"AHP Krauss","year":"2004","unstructured":"Krauss AHP, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004;49:S5\u201311.","journal-title":"Surv Ophthalmol."},{"key":"282_CR56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1350-9462(99)00006-3","volume":"19","author":"MF Sugrue","year":"2000","unstructured":"Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19:87\u2013112.","journal-title":"Prog Retin Eye Res."},{"key":"282_CR57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0002-9394(54)92027-9","volume":"37","author":"B Becker","year":"1954","unstructured":"Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox. Am J Ophthalmol. 1954;37:13\u20135.","journal-title":"Am J Ophthalmol."},{"key":"282_CR58","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0039-6257(99)00108-3","volume":"44","author":"L DeSantis","year":"2000","unstructured":"DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44:S119\u201329.","journal-title":"Surv Ophthalmol."},{"key":"282_CR59","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/archopht.1977.04450080088009","volume":"95","author":"DL Epstein","year":"1977","unstructured":"Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects: serum chemical analysis. Arch Ophthalmol. 1977;95:1378\u201382.","journal-title":"Arch Ophthalmol."},{"key":"282_CR60","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0002-9394(98)00095-6","volume":"126","author":"LH Silver","year":"1998","unstructured":"Silver LH. The Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt\u2122), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126:400\u20138.","journal-title":"Am J Ophthalmol."},{"key":"282_CR61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/jop.1997.13.23","volume":"13","author":"TH Maren","year":"1997","unstructured":"Maren TH, Conroy CW, Wynns GC, Levy NS. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharm Ther. 1997;13:23\u201330.","journal-title":"J Ocul Pharm Ther."},{"key":"282_CR62","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archopht.1995.01100120044006","volume":"113","author":"CB Toris","year":"1995","unstructured":"Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humour dynamics in human eyes. Arch Ophthalmol. 1995;113:1514\u20137.","journal-title":"Arch Ophthalmol."},{"key":"282_CR63","first-page":"763","volume":"23","author":"M Detry-Morel","year":"2000","unstructured":"Detry-Morel M, Dutrieux C. Treatment of glaucoma with brimonidine (Alphagan 0.2\u00a0%). J Fr Ophtalmol. 2000;23:763\u20138.","journal-title":"J Fr Ophtalmol."},{"key":"282_CR64","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0161-6420(95)31000-7","volume":"102","author":"CB Toris","year":"1995","unstructured":"Toris CB, Tafoya ME, Camras CB, et al. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102:456\u201361.","journal-title":"Ophthalmology."},{"key":"282_CR65","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1001\/archopht.117.5.586","volume":"117","author":"TL Maus","year":"1999","unstructured":"Maus TL, Nau C, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 1999;117:586\u201391.","journal-title":"Arch Ophthalmol."},{"key":"282_CR66","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/B978-0-7020-5193-7.00055-8","volume-title":"Glaucoma: medical diagnosis and therapy","author":"AC Reynolds","year":"2015","unstructured":"Reynolds AC. Alpha agonists. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma: medical diagnosis and therapy. London: Elsevier Saunders; 2015. p. 566\u201376."},{"key":"282_CR67","doi-asserted-by":"crossref","unstructured":"Gerente VM, Biondi AC, Barbosa CP, et al. Effect of brimonidine tartrate 0.15\u00a0% on scotopic pupil: controlled trial. J Ocul Pharm Ther. 2007;23:476\u2013480.","DOI":"10.1089\/jop.2007.0017.R1"},{"key":"282_CR68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00061198-200204000-00007","volume":"11","author":"LJ Katz","year":"2002","unstructured":"Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119\u201326.","journal-title":"J Glaucoma."},{"key":"282_CR69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0008-4182(02)80094-1","volume":"37","author":"P Blondeau","year":"2002","unstructured":"Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002;37:21\u20136.","journal-title":"Can J Ophthalmol."},{"key":"282_CR70","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00002512-199812030-00005","volume":"12","author":"JC Adkins","year":"1998","unstructured":"Adkins JC, Balfour JA. Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging. 1998;12:225\u201341.","journal-title":"Drugs Aging"},{"key":"282_CR71","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/0731-7085(95)01526-Q","volume":"13","author":"A Acheampong","year":"1995","unstructured":"Acheampong A, Tang-Liu DDS. Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography\/mass spectrometric assay. J Pharm Biomed Anal. 1995;13:995\u20131002.","journal-title":"J Pharm Biomed Anal."},{"key":"282_CR72","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/archopht.1974.03900060110004","volume":"91","author":"SM Drance","year":"1974","unstructured":"Drance SM, Bensted M, Schulzer M. Pilocarpine and intraocular pressure. Duration of effectiveness of 4 percent and 8 percent pilocarpine instillation. Arch Ophthalmol. 1974;91:104\u20136.","journal-title":"Arch Ophthalmol."},{"key":"282_CR73","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/bjo.62.5.302","volume":"62","author":"I Grierson","year":"1978","unstructured":"Grierson I, Lee WR, Abraham S. Effects of pilocarpine on the morphology of the human outflow apparatus. Br J Ophthalmol. 1978;62:302\u201313.","journal-title":"Br J Ophthalmol."},{"key":"282_CR74","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/B978-0-7020-5193-7.00056-X","volume-title":"Glaucoma: medical diagnosis and therapy","author":"LO Shiroma","year":"2015","unstructured":"Shiroma LO, Costa VP. Parasympathomimetics. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma: medical diagnosis and therapy. London: Elsevier Saunders; 2015. p. 577\u201382."},{"key":"282_CR75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archopht.1966.00970050203010","volume":"75","author":"P D\u2019Alena","year":"1966","unstructured":"D\u2019Alena P, Ferguson W. Adverse effects after glycerol orally and mannitol parenterally. Arch Ophthalmol. 1966;75:201\u20133.","journal-title":"Arch Ophthalmol."},{"key":"282_CR76","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/j.1875-9114.1981.tb03562.x","volume":"1","author":"MSB Frank","year":"1981","unstructured":"Frank MSB, Nahata MC, Hilty MD. Glycerol: a review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use. Pharmacotherapy. 1981;1:147\u201360.","journal-title":"Pharmacotherapy"},{"key":"282_CR77","first-page":"1","volume":"4","author":"EJ Higginbotham","year":"2010","unstructured":"Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1\u20139.","journal-title":"Clin Ophthalmol."},{"key":"282_CR78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.17925\/EOR.2010.04.01.23","volume":"4","author":"M Hopes","year":"2010","unstructured":"Hopes M, Broadway DC. Preservative-free treatment in glaucoma is a sensible and realistic aim for the future. Eur Ophthalmol Rev. 2010;4:23\u20138.","journal-title":"Eur Ophthalmol Rev."},{"key":"282_CR79","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00061198-200106000-00015","volume":"10","author":"WC Stewart","year":"2001","unstructured":"Stewart WC, Day DG, Holmes KT, et al. Effect of timolol 0.5\u00a0% gel and solution on pulmonary function in older glaucoma patients. J Glaucoma. 2001;10:227\u201332.","journal-title":"J Glaucoma."},{"key":"282_CR80","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0002-9394(02)01699-9","volume":"134","author":"PJ Lama","year":"2002","unstructured":"Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134:749\u201360.","journal-title":"Am J Ophthalmol."},{"key":"282_CR81","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0002-9394(14)73203-9","volume":"116","author":"SF Freedman","year":"1993","unstructured":"Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol. 1993;116:600\u201311.","journal-title":"Am J Ophthalmol."},{"key":"282_CR82","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1177\/0091270011420254","volume":"52","author":"L Quaranta","year":"2012","unstructured":"Quaranta L, Katsanos A, Floriani I, et al. Circadian intraocular pressure and blood pressure reduction with Timolol 0.5\u00a0% solution and Timogel 0.1\u00a0% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52:1552\u20137.","journal-title":"J Clin Pharmacol."},{"key":"282_CR83","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/bjo.82.8.862","volume":"82","author":"DC Broadway","year":"1998","unstructured":"Broadway DC, Drance SM. Glaucoma and vasospasm. Br J Ophthalmol. 1998;82:862\u201370.","journal-title":"Br J Ophthalmol."},{"key":"282_CR84","first-page":"45","volume":"87","author":"C Meuche","year":"1990","unstructured":"Meuche C, Heidrich H, Bleckmann H. Raynaud syndrome following timolol-containing eyedrops. Fortschr Ophthalmol. 1990;87:45\u20137.","journal-title":"Fortschr Ophthalmol."},{"key":"282_CR85","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/j.1552-4604.1992.tb05777.x","volume":"32","author":"C Franssen","year":"1992","unstructured":"Franssen C, Wollersheim H, de Haan A, et al. The influence of different beta-blocking drugs on the peripheral circulation in Raynaud\u2019s phenomenon and in hypertension. J Clin Pharmacol. 1992;32:652\u20139.","journal-title":"J Clin Pharmacol."},{"key":"282_CR86","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.ophtha.2014.02.009","volume":"121","author":"AP Khawaja","year":"2014","unstructured":"Khawaja AP, Chan MP, Broadway DC, et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology. 2014;121:1501\u20137.","journal-title":"Ophthalmology."},{"key":"282_CR87","first-page":"S255","volume":"8","author":"JJ Spooner","year":"2002","unstructured":"Spooner JJ, Bullano M, Ikeda LI, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care. 2002;8:S255\u201361.","journal-title":"Am J Manag Care."},{"key":"282_CR88","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2415-14-32","volume":"14","author":"H Cate","year":"2014","unstructured":"Cate H, Bhattacharya D, Clark A, et al. Improving adherence to glaucoma medication: a randomized controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study). BMC Ophthalmol. 2014;14:32.","journal-title":"BMC Ophthalmol."},{"key":"282_CR89","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0039-6257(90)90090-I","volume":"35","author":"SL Gerber","year":"1990","unstructured":"Gerber SL, Cantor LB, Brater DC. Systemic drug interactions with topical glaucoma medications. Surv Ophthalmol. 1990;35:205\u201318.","journal-title":"Surv Ophthalmol."},{"key":"282_CR90","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0379-0738(03)00056-2","volume":"133","author":"H Kinoshita","year":"2003","unstructured":"Kinoshita H, Taniguchi T, Nishiguchi M, et al. An autopsy case of combined drug intoxication involving verapamil, metoprolol and digoxin. Forensic Sci Int. 2003;133:107\u201312.","journal-title":"Forensic Sci Int."},{"key":"282_CR91","unstructured":"Thomson Healthcare Inc. Interaction effects of apraclonidine, brimonidine, and monoamine oxidase inhibitors. Micromedex 2007 and United States Pharmacopeia 2004."},{"key":"282_CR92","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archopht.116.12.1625","volume":"116","author":"KF Tabbara","year":"1998","unstructured":"Tabbara KF, Al-Faisal Z, Al-Rashed W. Interaction between acetazolamine and cyclosporine. Arch Ophthalmol. 1998;116:832\u20133.","journal-title":"Arch Ophthalmol."},{"key":"282_CR93","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archopht.1981.03930010102012","volume":"99","author":"RF Steinert","year":"1981","unstructured":"Steinert RF, Thomas JV, Boger WP 3rd. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol. 1981;99:100\u20133.","journal-title":"Arch Ophthalmol."},{"key":"282_CR94","first-page":"3145","volume":"32","author":"RF Brubaker","year":"1991","unstructured":"Brubaker RF. Flow of aqueous humor in humans. Invest Ophthalmol Vis Sci. 1991;32:3145\u201366.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"282_CR95","first-page":"83","volume":"38","author":"HA Quigley","year":"1997","unstructured":"Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83\u201391.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"282_CR96","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1016\/0039-6257(83)90142-X","volume":"28","author":"TJ Zimmerman","year":"1983","unstructured":"Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 1983;28:S252\u20138.","journal-title":"Surv Ophthalmol."},{"key":"282_CR97","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00061198-199201020-00012","volume":"1","author":"RN Weinreb","year":"1992","unstructured":"Weinreb RN. Compliance with medical treatment of glaucoma. J Glaucoma. 1992;1:134\u20138.","journal-title":"J Glaucoma."},{"key":"282_CR98","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ajo.2003.10.029","volume":"137","author":"GF Schwartz","year":"2004","unstructured":"Schwartz GF. Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma. Am J Ophthalmol. 2004;137:S1\u20132.","journal-title":"Am J Ophthalmol."},{"key":"282_CR99","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1378\/chest.130.1_suppl.65S","volume":"130","author":"R Horne","year":"2006","unstructured":"Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006;130:65S\u201372S.","journal-title":"Chest."},{"key":"282_CR100","doi-asserted-by":"crossref","unstructured":"Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.","DOI":"10.1002\/14651858.CD000011.pub3"},{"key":"282_CR101","first-page":"S278","volume":"8","author":"GF Schwartz","year":"2002","unstructured":"Schwartz GF, Platt R. Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications. Am J Manag Care. 2002;8:S278\u201380.","journal-title":"Am J Manag Care."},{"key":"282_CR102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1475-1313.2003.00155.x","volume":"24","author":"S Deokule","year":"2004","unstructured":"Deokule S, Sadiq S, Shah S. Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms. Ophthalmic Physiol Opt. 2004;24:9\u201315.","journal-title":"Ophthalmic Physiol Opt."},{"key":"282_CR103","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","volume":"12","author":"JC Tsai","year":"2003","unstructured":"Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers and glaucoma; a systematic classification. J Glaucoma. 2003;12:393\u20138.","journal-title":"J Glaucoma."},{"key":"282_CR104","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ophtha.2008.09.004","volume":"116","author":"CO Okeke","year":"2009","unstructured":"Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116:191\u20139.","journal-title":"Ophthalmology."},{"key":"282_CR105","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0002-9394(86)90940-2","volume":"101","author":"MA Kass","year":"1986","unstructured":"Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol. 1986;101:524\u201330.","journal-title":"Am J Ophthalmol."},{"key":"282_CR106","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0002-9394(14)74225-4","volume":"103","author":"MA Kass","year":"1987","unstructured":"Kass MA, Gordon M, Morley RE Jr, et al. Compliance with topical timolol treatment. Am J Ophthalmol. 1987;103:188\u201393.","journal-title":"Am J Ophthalmol."},{"key":"282_CR107","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bjo.74.8.477","volume":"74","author":"AJ Winfield","year":"1990","unstructured":"Winfield AJ, Jessiman D, Williams A, et al. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74:477\u201380.","journal-title":"Br J Ophthalmol."},{"key":"282_CR108","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2005.10.034","volume":"113","author":"B Sleath","year":"2006","unstructured":"Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431\u20136.","journal-title":"Ophthalmology."},{"key":"282_CR109","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533\u20134.","journal-title":"Am J Ophthalmol."},{"key":"282_CR110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0002-9394(14)71282-6","volume":"116","author":"WC Stewart","year":"1993","unstructured":"Stewart WC, Chorak RP, Hunt HH, et al. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116:176\u201381.","journal-title":"Am J Ophthalmol."},{"key":"282_CR111","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.ophtha.2007.10.031","volume":"115","author":"J Caprioli","year":"2008","unstructured":"Caprioli J, Coleman AL. Intraocular pressure fluctuation: a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention Study. Ophthalmology. 2008;115:1123\u20139.","journal-title":"Ophthalmology."},{"key":"282_CR112","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5301\/EJO.2010.6112","volume":"21","author":"GC Rossi","year":"2011","unstructured":"Rossi GC, Pasinetti GM, Scudeller L, et al. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21:410\u20134.","journal-title":"Eur J Ophthalmol."},{"key":"282_CR113","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","volume":"118","author":"B Sleath","year":"2011","unstructured":"Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118:2398\u2013402.","journal-title":"Ophthalmology."},{"key":"282_CR114","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","volume":"140","author":"BL Nordstrom","year":"2005","unstructured":"Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598\u2013606.","journal-title":"Am J Ophthalmol."},{"key":"282_CR115","first-page":"233","volume":"26","author":"SC Patel","year":"1995","unstructured":"Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg. 1995;26:233\u20136.","journal-title":"Ophthalmic Surg."},{"key":"282_CR116","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"CM Olthoff","year":"2005","unstructured":"Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology. 2005;112:953\u201361.","journal-title":"Ophthalmology."},{"key":"282_CR117","unstructured":"Sackett D, Jackett D, Snow J. Magnitude and measurement of compliance. In: Haynes B, Wayne Taylor D, Sackett D (eds.) Compliance in healthcare. Baltimore, London: The John Hopkins University Press; 1979. pp. 11\u201322."},{"key":"282_CR118","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/eye.2008.103","volume":"23","author":"J Lacey","year":"2009","unstructured":"Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. Eye. 2009;23:924\u201332.","journal-title":"Eye."},{"key":"282_CR119","first-page":"145","volume":"35","author":"C Cooper","year":"2013","unstructured":"Cooper C, Dennison E, Edwards M, Litwic A. Epidemiology of osteoarthritis. Medicographia. 2013;35:145\u201351.","journal-title":"Medicographia."},{"key":"282_CR120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mds.870130105","volume":"13","author":"ED Louis","year":"1998","unstructured":"Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord. 1998;13:5\u201310.","journal-title":"Mov Disord."},{"issue":"63\u201375","key":"282_CR121","first-page":"e2","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer Dement. 2013;9(63\u201375):e2.","journal-title":"Alzheimer Dement."},{"key":"282_CR122","first-page":"775","volume":"14","author":"MA Kass","year":"1982","unstructured":"Kass MA, Hodapp E, Gordon M, et al. Part I. Patient administration of eyedrops: interview. Ann Ophthalmol. 1982;14:775\u20139.","journal-title":"Ann Ophthalmol."},{"key":"282_CR123","first-page":"889","volume":"14","author":"MA Kass","year":"1982","unstructured":"Kass MA, Hodapp E, Gordon M, et al. Patient administration of eyedrops: observation. Part II. Ann Ophthalmol. 1982;14:889\u201393.","journal-title":"Ann Ophthalmol."},{"key":"282_CR124","first-page":"29","volume":"105","author":"T Tsai","year":"2007","unstructured":"Tsai T, Robin AL, Smith JP III. An evaluation of how glaucoma patients use topical medications: a pilot study. Trans Am Ophthalmol Soc. 2007;105:29\u201335.","journal-title":"Trans Am Ophthalmol Soc."},{"key":"282_CR125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/17434440.4.2.261","volume":"4","author":"MY Kahook","year":"2007","unstructured":"Kahook MY. Developments in dosing aids and adherence devices for glaucoma therapy: current and future perspectives. Expert Rev Med Devices. 2007;4:261\u20136.","journal-title":"Expert Rev Med Devices."},{"issue":"3","key":"282_CR126","first-page":"396","volume":"13","author":"DA Sclar","year":"1991","unstructured":"Sclar DA, Skaer TL, Chin A, et al. Effectiveness of the C CapTM in promoting prescription refill compliance among patients with glaucoma. Clin Ther. 1991;13(3):396\u2013400.","journal-title":"Clin Ther."},{"key":"282_CR127","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/00002512-200421120-00004","volume":"21","author":"C Hughes","year":"2004","unstructured":"Hughes C. Medication non-adherence in the elderly. Drugs Aging. 2004;21:793\u2013811.","journal-title":"Drugs Aging."},{"key":"282_CR128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/eye.2012.294","volume":"27","author":"H Cate","year":"2013","unstructured":"Cate H, Battacharya D, Clark A, et al. Patterns of adherence behaviour for patients with glaucoma. Eye. 2013;27:545\u201353.","journal-title":"Eye."},{"key":"282_CR129","doi-asserted-by":"crossref","unstructured":"Giaconi JA, Law SK, Coleman AL, Caprioli J (eds). Pearls of glaucoma management. 1st edition. Heidleberg: Springer; 2010. p. 235.","DOI":"10.1007\/978-3-540-68240-0"},{"key":"282_CR130","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2105\/AJPH.83.5.711","volume":"83","author":"JH Gurwitz","year":"1993","unstructured":"Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: Adherence by the elderly. Am J Pub Health. 1993;83:711\u20136.","journal-title":"Am J Pub Health."},{"key":"282_CR131","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/10807680260362687","volume":"18","author":"SA Taylor","year":"2002","unstructured":"Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002;18:401\u20139.","journal-title":"J Ocul Pharmacol Ther."},{"key":"282_CR132","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.ophtha.2013.01.002","volume":"120","author":"DS Chang","year":"2013","unstructured":"Chang DS, Friedman DS, Frazier T, et al. Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Ophthalmology. 2013;120:1396\u2013402.","journal-title":"Ophthalmology."},{"key":"282_CR133","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","volume":"116","author":"JC Tsai","year":"2009","unstructured":"Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116:S30\u20136.","journal-title":"Ophthalmology."},{"key":"282_CR134","first-page":"2089","volume":"71","author":"FJ Domino","year":"2005","unstructured":"Domino FJ. Improving adherence to treatment for hypertension. Am Fam Physician. 2005;71:2089\u201390.","journal-title":"Am Fam Physician"},{"key":"282_CR135","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.CIR.95.4.1085","volume":"95","author":"NH Miller","year":"1997","unstructured":"Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation. 1997;95:1085\u201390.","journal-title":"Circulation."},{"key":"282_CR136","first-page":"15","volume":"7","author":"J Sheppard","year":"2003","unstructured":"Sheppard J, Warner J, Kelley K. An evaluation of the effectiveness of a nurse-led glaucoma monitoring clinic. Ophthalmic Nurs. 2003;7:15\u201321.","journal-title":"Ophthalmic Nurs."},{"key":"282_CR137","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1755-3768.2012.02571.x","volume":"91","author":"HJ Beckers","year":"2013","unstructured":"Beckers HJ, Webers CA, Busch MJ, et al. Adherence improvement in Dutch glaucoma patients: a randomized controlled trial. Acta Ophthalmol. 2013;91:610\u20138.","journal-title":"Acta Ophthalmol."},{"key":"282_CR138","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/bmj.2.6197.1031","volume":"2","author":"SE Norell","year":"1979","unstructured":"Norell SE. Improving medication compliance: a randomised clinical trial. Br Med J. 1979;2:1031\u20133.","journal-title":"Br Med J"},{"key":"282_CR139","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.ophtha.2009.05.026","volume":"116","author":"CO Okeke","year":"2009","unstructured":"Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology. 2009;116:2286\u201393.","journal-title":"Ophthalmology."},{"key":"282_CR140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/IJG.0b013e31819c4679","volume":"19","author":"JE Stryker","year":"2010","unstructured":"Stryker JE, Beck AD, Primo SA, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010;19:66\u201372.","journal-title":"J Glaucoma."},{"key":"282_CR141","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/archinte.167.6.540","volume":"167","author":"S Kripalani","year":"2007","unstructured":"Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540\u201350.","journal-title":"Arch Intern Med."},{"key":"282_CR142","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/eye.2011.269","volume":"26","author":"TA Gray","year":"2012","unstructured":"Gray TA, Fenerty C, Harper R, et al. Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial. Eye. 2012;26:407\u201317.","journal-title":"Eye."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-015-0282-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0282-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T17:59:28Z","timestamp":1566928768000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-015-0282-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":142,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1007\/s40266-015-0282-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}